Validation experiment designed to validate causal mechanisms targeting β-catenin, AGER1 in animal models (species not specified). Primary outcome: HCC tumor development and growth
Animal model experiments investigating how AGEs promote hepatocellular carcinoma development through enhanced ECM viscoelasticity combined with oncogenic β-catenin signaling. The study examined HCC induction in animal models with type 2 diabetes mellitus, focusing on the mechanical properties of the liver ECM and how AGE accumulation affects collagen architecture. The experiments included interventions to inhibit AGE production, reconstitute AGE clearance receptor AGER1, and break AGE-mediated collagen cross-links to assess their effects on viscoelasticity and HCC growth.
AGE manipulation studies, AGER1 reconstitution, collagen cross-link disruption, tumor monitoring
AGE inhibition and AGER1 reconstitution reduce viscoelasticity and HCC growth
Reduced tumor burden with AGE pathway interventions
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.